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Abstract 
 
Background: The prevalence of diabetes mellitus is increasing rapidly in both developed and developing countries. There 
are various conventional medicines used for the management of the disease, but there is also increased interest in the use of 
traditional herbal medicines. Although the concepts of illness and diseases in traditional medicine may differ from 
conventional medicine the outcomes are similar. The antihyperglycemic effects of various herbal medicines prescribed by 
traditional healers in the management of diabetes mellitus have been proven scientifically using several in-vitro and in-vivo 
models as well as clinical studies in humans.  
Materials and methods: Literature search was done in several databases. Firstly, the search was conducted using the key 
terms: diabetes mellitus and traditional medicine, diabetes mellitus and herbs, diabetes mellitus and plants, traditional 
concepts of health and sickness and diabetes mellitus. After identifying the herbs or plants used in diabetes a search was 
then conducted by name of herb and efficacy in management of diabetes mellitus. 
Results: This review highlights the similarities and differences in mechanisms of action of various traditional herbal 
medicines and conventional medicines. The major observation is that, herbal medicines often have multiple mechanisms of 
action ideally making them combination therapies. The review further highlights the need to develop an algorithm of a 
minimum battery of in-vitro and animal studies that can provide solid evidence of the potential of traditional medicines as 
anti-diabetic treatments. 
Conclusion: Traditional herbal medicines often have multiple phytoconstituents and hence multiple mechanisms of action 
ideally making them combination therapies. 
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Introduction 
 
Normal glucose homeostasis is tightly controlled by three interconnected and interrelated processes: (1) glucose 
production in the liver through gluconeogenesis and glycogenolysis, (2) glucose uptake and utilization by peripheral tissues 
mainly skeletal muscle and adipose tissue, and (3) the action of insulin and counter regulatory hormones (including 
glucagon, somatostatin, growth hormone and corticosteroids) (Kumar et al., 2013). The metabolic effects of insulin can be 
summarized as anabolic, with increase in glycogenesis, decrease in gluconeogenesis and glycogenolysis, increase in protein 
synthesis and decrease in degradation of lipids. 
Diabetes Mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia as a result of deficiency in 
insulin secretion, insulin action or often a combination of both.  According to the International Diabetes Federation (IDF) in 
2015, approximately 415 million people in the world live with DM, the majority of whom are between the age of 40 – 59 
years and 80% live in low to middle income countries (International Diabetes Federation, 2015). The prevalence of DM is 
increasing rapidly in both developed and developing countries. This increase is more pronounced in countries undergoing a 
transition from traditional to modern lifestyles (International Diabetes Federation, 2015). IDF, in 2015 also reported that 
approximately 673 billion United States dollars, which is 12% of global health expenditure was spent on management of 
diabetes and its complications (International Diabetes Federation, 2015).  
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There are two major types of diabetes mellitus. Type 1 DM is characterized by an absolute deficiency of insulin 
secretion caused, most commonly, by autoimmune destruction of the pancreatic beta cells that produce the insulin (Kumar 
et al., 2013). Type 2 DM is usually caused by a combination of peripheral insulin resistance and an inadequate 
compensatory response of insulin secretion by the pancreatic beta cells (Kumar et al., 2013). Regardless of the type of DM, 
the clinical presentation and progression are the same. Similarly the complications of uncontrolled disease are the same, 
affecting the microvascular (kidneys, eyes and nerves) and macrovascular systems (Fowler, 2008).  
 Diabetes can be diagnosed by any of four criteria. The first criterion is glycated hemoglobin (HbA1c) 
level ≥6.5%. This criterion is also considered the gold standard to assess adequacy of therapy and management of diabetes. 
The second criterion is a fasting blood glucose level ≥7mmol/L. Fasting is defined as no caloric intake for at least 8 hours.  
Fasting blood glucose level is the most commonly used in developing countries since HbA1c testing may not be readily 
available. The third criterion is a 2-hour blood glucose level ≥11.1mmol during a 75g oral glucose tolerance test. The last 
criterion is a random blood glucose ≥11.1mmol with classic symptoms of hyperglycemia which are polyuria, polydipsia 
and polyphagia (Kumar et al., 2013). 
The pathogenesis of the long term complications of DM are multifactorial but persistent hyperglycemia 
(glucotoxicity) seems to be the key factor (Kumar et al., 2013). Formation of advanced glycation end products which give 
rise to release of pro-inflammatory cytokines from macrophages, generation of reactive oxygen species in endothelial cells 
and increased pro-coagulant activity on endothelial cells is one mechanism that leads to development of both macrovascular 
and microvascular complications (Kumar et al., 2013). The reactive oxygen species are also implicated in worsening 
pancreatic beta cell dysfunction in diabetes mellitus (Kumar et al., 2013). Most of the diabetic complications are also 
related to the presence of glycated products in the blood and generation of free radicals (Kumar et al., 2013). Therefore, use 
of treatments that have antioxidant properties may delay or stop the development and progression of diabetes complications 
as well as promote regeneration of pancreatic beta cells. 
Management of DM using conventional drugs is achieved through supplementation of insulin, increasing insulin 
secretion from the pancreas, increasing insulin sensitivity in peripheral tissues especially skeletal muscle, decreasing the 
rate of glucose absorption in the gut and increasing glucose excretion via the kidney. The drugs can be classified as 
insulins, insulin secretagogues (sulfonylureas, meglitinides, glucagon like peptide agonists, dipeptidylpeptidase IV 
inhibitors), insulin sensitizers (metformin, thiazolidinediones), alpha glucosidase inhibitors (acarbose and miglitol) and 
selective sodium-glucose transporter 2 inhibitors (Inzucchi et al., 2012; Nair & Wilding, 2010).  
Despite the availability of the various classes of these conventional medicines the morbidity and mortality due to 
DM continues to increase globally (International Diabetes Federation, 2015). This is partly because none of the medicines 
results in cure of the disease. With disease progression, Type 2 DM patients move from single oral drug regimens to oral 
combination therapy and eventually to combination therapy that includes insulin injections (Inzucchi et al., 2012). The use 
of the conventional drugs is also often associated with adverse side effects such as severe hypoglycemia (insulin, 
sulfonylureas), lactic acidosis and vitamin B12 deficiency (biguanides), peripheral edema, bone weakening and hence 
fractures (thiazolidinediones) and abdominal discomfort (alpha-glucosidase inhibitors) (Lorenzati et al., 2010). Further, the 
cost of these conventional medicines is beyond the reach of many people who live in low resource settings such as Africa 
(International Diabetes Federation, 2015). Therefore, the search for more effective, cheaper and safer alternative treatments 
remains essential. 
Herbal medicines are commonly used in traditional medicine (TM) practice for the management of non-
communicable diseases including DM (Z. Wang et al., 2013; World Health Organisation, 2012). People use herbal 
medicines for various reasons. Herbal medicines are  perceived to have higher effectiveness,  less side effects since they are 
of natural origin, relatively low cost and more accessible in remote areas (World Health Organisation, 2012). Therefore, 
research in these perceived benefits has become even more important to promote rational use, improve the action and 
stability of the herbal medicines by improving the formulations, and identify new chemical entities for management of DM. 
Phytochemical screening and isolation has identified various phytoconstituents with antidiabetic effects. Among 
the phytoconstituents, the main actives are alkaloids, amino acids, glycosides, guanidine, steroids, polysaccharides, 
proteins, terpenoids, inorganic ions and peptidoglycans. This review article highlights the potential mechanisms of action of 
various traditional herbal medicines that were shown to be efficacious in various models of diabetes. The review discusses 
the similarities and differences between the mechanisms of action of the herbal medicines and conventional medicines used 
in the management of diabetes mellitus. The review also highlights the potential role of herbal medicines in the prevention 
and/or treatment of diabetes complications. The review then concludes with suggestions of some key parameters that can be 
used to validate effectiveness of traditional medicines and argues that society may benefit more if science not only 
emphasized isolation of active chemical entities and drug development, but focuses on improving the action of the 
traditional herbal medicines in the forms used by traditional healers. This will have far greater efficiency in research as well 
as impact on morbidity and mortality due to diabetes mellitus. 
 
Concepts of Health and Sickness in Traditional Medicine and Diabetes Mellitus 
 
The conventional medicine approach is founded on empirical evidence, which has led to the isolation of 
observable and tangible etiological factors in the understanding and treatment of illness. A similar approach has been 
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adopted in developing the therapeutic procedures to combat the causes of illness. This approach largely revolves around 
finding active compounds specific for the desired effect. In the traditional healing context, health is viewed not as an 
isolated phenomenon but is encompassing and includes other factors that may not be considered in conventional medicine. 
Good health is therefore defined by means of a harmonious working and co-ordination of this integrated view (Busia, 2005;  
Okpako, 1999). Therefore it is within this world-view and metaphysics that appropriate and accurate African concepts of 
health, diseases and treatment can be derived and understood (Dlamini, 2006; Omonzejele, 2008). As the traditional 
concepts of health and illness are encompassing, the approach to management and treatment of illness is holistic 
(Omonzejele, 2008). Theoretical assumptions that traditional healers make about the origin of illness are consistent with the 
methods of treatment of the illness. While medical scientists may regard this approach as unscientific, users and 
practitioners of TM appreciate its rationality in the context it operates (Okpako, 1999).  
Similarly, there are a number of differences between conventional and traditional medicine approaches to the 
management of diabetes mellitus. Conventional medicines used in DM target specific receptors for them to bring about 
therapeutic value, and normally one chemical entity has one mechanism of action. Unlike conventional medicines, 
traditional herbal medicines may contain various active ingredients targeting multiple mechanisms of action, ideally making 
the traditional herbal medicines combination therapies. In TM practice, the focus is not only on the blood glucose but about 
the wellness of the human being, hence the multiple phytoconstituents and multiple herbs normally incorporated in 
traditional herbal mixtures (Baldé et al., 2006; Peltzer et al., 2001; Tong et al., 2012). Whilst the conventional medicine 
approach defines DM as incurable, in African traditional medicine DM is a temporary condition that can be cured with the 
help of the ancestors (Awah, 2006). 
 
Efficacy of traditional herbal medicines used to treat diabetes mellitus 
 
The use of TM in the management of DM dates back to many centuries ago especially in Chinese and Indian TM 
practice. As later discussed, several herbal medicines have been shown to reduce blood glucose levels or reduce progression 
of diabetes complications. Some of the traditional medicines that have been extensively studied and have shown definitive 
efficacy as antidiabetic agents are discussed below. 
Accumulating pieces of evidence demonstrate that leaves of Gymnema syvestre have antidiabetic properties.  In 
1990, Shanmugasundaram et al evaluated the effectiveness of G. sylvestre in 27 Type 1 DM patients in combination with 
insulin therapy (Shanmugasundaram et al., 1990). The extracts at the dose of 400mg daily for 18 months in combination 
with insulin therapy, significantly decreased fasting blood glucose, HbA1C and serum lipids of the patients compared to a 
similar group who received insulin only (Shanmugasundaram et al., 1990).   In another study, 200mg of ethanolic extract of 
G. sylvestre significantly reduced fasting blood glucose level and HbA1C in diabetic patients (Nahas & Moher, 2009). In an 
open-label clinical trial with 58 Type 2 diabetic patients, 500mg G. sylvestre   leaf extracts taken daily for 3 months (Kumar 
et al., 2010) induced  a significant reduction in polyphagia, blood glucose and HbA1C compared to the control group. 
Administration of G. sylvestre  to Type 2 DM patients at a dose of 1g/day for 2 months, also led to significant decreases in 
fasting blood glucose and early post-prandial blood glucose levels accompanied by increases in insulin and C-peptide in the 
blood (Al-Romaiyan et al., 2010). In the same study, extracts of G. sylvestre stimulated insulin secretion from isolated 
human islets of Langerhans (Al‐Romaiyan et al., 2010). 
Trigonella foenum-graecum seed was used in ancient Egypt as a remedy for DM and spread to Asian countries 
such as China and India (Bawadi et al., 2009). T. foenum-graeceum was reported to have hypoglycemic effects in rats as 
early as 1974 (Mishkinsky et al., 1974). In a study in diabetic patients, insulin levels were significantly higher in the T. 
foenum-graecum treatment group compared to the placebo treatment group (Mathern et al., 2009). Sharma et al, 1990, 
showed that the defatted seeds of T. foenum-graecum administered to Type 1 DM patients at a dose of 100g daily for 10 
days significantly lowered fasting blood glucose, total cholesterol, low-density lipoproteins and tryglycerides (Sharma et 
al., 1990). A meta-analysis on the effect of herbal supplement in Type 2 DM patients showed that T. foenum-graecum 
reduced HbA1C by 1.13% (P=0.03) (Suksomboon et al., 2011). In a double blind placebo controlled study, T. foenum-
graecum was shown to improve glycemic control and insulin resistance in mild Type 2 diabetic patients (Gupta et al., 
2001).  
Momordica charantia is one of the most extensively studied herbal medicines that is used in the management of 
DM. The extracts of M. charantia reduced blood glucose levels and improved glucose tolerance comparable to 
conventional medicines in diabetic rat models (Ahmed et al., 2004; Ahmed et al., 2001; Sarkar et al., 1996; Virdi et al., 
2003; Welihinda et al., 1986). The efficacy of M. charantia in humans has also been documented (Welihinda et al., 1986). 
Malik et al. 2009, compared the effects of M. charantia to rosiglitazone (thiazolidinedione which has since been banned 
because of cardiovascular side effects) in 25 Type 2 DM patients (Malik et al., 2009). Administration of 55ml/day of M. 
charantia juice for 5 months resulted in better control of diabetes and its related complications especially diabetes 
retinopathy and myocardial infarction compared to rosiglitazone (Malik et al., 2009). Ahmad et al. (1999) reported that 
drinking an aqueous suspension of the vegetable pulp of M. charantia resulted in a significant reduction in fasting blood 
glucose and post-prandial blood glucose levels in 86 out of 100 patients with Type 2 DM (Ahmad et al., 1999). 
One of the most successful stories of TM research in DM was the discovery of metformin, a biguanide which is 
currently the backbone of Type 2 DM treatment. Metformin was developed based on the findings that guanidine like 
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compounds isolated from Galega officinalis significantly reduced blood glucose levels (Bailey & Day, 2004). Guanidine 
compounds however, were too toxic for clinical use (Muller & Rheinwein, 1927). Through a series of testing and research, 
biguanides were then developed and shown to retain the antidiabetic effects of the guanidine like compounds yet safer to 
use clinically (Hesse & Taubmann, 1929; Mehnert & Seitz, 1958; Slotta & Tsesche, 1929; Sterne, 1957; Ungar et al., 
1957). 
The success of metformin discovery has not been emulated with any other herbal medicine. This is possibly 
because other herbal medicines do not have one single chemical entity that is as highly active in the management of DM. 
Rather, a synergistic combination of effects and mechanisms by various phytoconstituents is responsible for the blood 
glucose lowering properties. This can be a lesson to the scientific community to not only look to the road of drug discovery 
but to try and improve the action of these herbal medicines as close to their traditional use as possible. Investing into 
research on the formulations of these raw herbal medicines may help in improving their stability and safety, which may 
reduce the marginalization of traditional herbal medicine use in DM. 
 
Mechanisms of action of traditional herbal medicines in DM management 
Antioxidant properties 
 
Free radicals may be responsible for development and progression of DM as well as development and progression 
of DM complications (Baynes & Thorpe, 1999). The free radicals that are most implicated in DM and its complications are 
the superoxides, hydroxyl and lipid peroxides (Oberley, 1988). Therefore, antioxidants could potentially slow down, 
prevent and treat some of the complications. A number of herbal medicines have been proven to have antioxidant 
properties. These properties are suggested to be partly responsible for the antidiabetic effects.  
In one study, extracts of Emblica officinalis, Terminalia belerica, Terminalia chebula and a combination of all the 
3 extracts were shown to scavenge free radicals in-vitro (Sabu & Kuttan, 2002).  Green tea polyphenols (GTP) from 
Camellia sinensis were shown to have free radical scavenging properties both in vitro and in vivo studies (Sabu et al., 
2002). Administration of GTP for 18 days resulted in significantly lower blood glucose levels in alloxan induced diabetic 
rats. Administration of GTP (100mg/kg) was also shown to considerably reverse alloxan-induced pancreatic cell damage 
(Sabu et al., 2002). T. foenum-graecum extracts reduced oxidative stress, lowered lipid peroxidation and significantly 
increased antioxidant systems in animal models of DM (Annida et al., 2005).  
Berberine, an isoquinoline alkaloid from Coptis sinensis was shown to reverse renal dysfunction in rats with 
diabetic nephropathy by decreasing blood glucose levels, reduction of the oxidative stress and suppressing the polyol 
pathway (sorbitol-aldose reduction) which is implicated in development of diabetic complications (Liu et al., 2008). Rhus 
hirta fruit extracts, Solidago Canadensis root extracts, Amarantus hypochondriacus  seed extracts have higher free radical 
scavenging properties than ascorbic acid hence maybe utilized in preventing, reducing or stopping the progression of 
pancreatic beta cell destruction caused by free radicals as well as halting the progression of diabetes complications 
(McCune & Johns, 2002; Nsimba et al., 2008). The antioxidant properties of M. charantia  have also been associated with 
the antidiabetic activity of the plant extracts (Kubola & Siriamornpun, 2008; Park et al., 2007; Sen et al., 2014). 
The anti-oxidant properties of traditional herbal medicines make them potential supplements to conventional 
medicines to reduce and/or reverse pancreatic beta cell damage and hence development and progression of the 
complications of DM. 
 
Increase in insulin secretion 
 
In advanced type 2 DM there is reduced insulin secretion making insulin secretagogues logical options for 
management of the disease. Some herbal extracts were shown to increase insulin secretion though the mechanisms have not 
been clearly elucidated. G. syvestre leaf extracts were shown to stimulate insulin secretion in-vitro by increasing membrane 
permeability of pancreatic beta cells resulting in influx of calcium which then leads to insulin secretion (Persaud et al., 
1999). Slow acting protein extract from fruit pulp of M. charantia increased insulin secretion in Streptozotocin-induced 
diabetic rats as evidenced by increased plasma insulin concentrations in treated compared to control animals (Yibchok-anun 
et al., 2006). The increase was attributed to activation of glucokinase hence lowering the glucose threshold for insulin 
secretion in the pancreas (Rathi et al., 2002). Similarly, T. foenum-graecum extracts increased insulin secretion in animal 
studies; the increase being attributed to 4-hydroxyleucine, an amino acid mimicking the insulin secreting properties of the 
gluconeogenic amino acids arginine and leucine (Broca et al., 2000). 
 
Regeneration of the pancreatic beta cells 
 
Destruction of the pancreatic beta cells is responsible for the onset of Type 1 DM and may also occur in late stage 
Type 2 DM especially when the patients are taking insulin secretagogues particularly the sulfonylureas (Del Guerra et al., 
2005; Maedler et al., 2005). Currently, there is no conventional medicine that works by promoting the regeneration of 
pancreatic beta cells. A formulation that has such properties would be novel and potentially could cure both type 1 and type 
2 DM. 
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Leaf extracts of G. sylvestre were shown to promote pancreatic beta cell regeneration in alloxan-induced diabetic 
Wistar rats (AHMED et al., 2010). Extracts of G. syvestre increased both the pancreas mass and the liver glycogen content 
levels (AHMED et al., 2010). Berberine, from Coptis sinensis restored damaged pancreatic tissues in alloxan induced 
diabetic rats (Liu et al., 2008; Zhou et al., 2009). Pancreatic beta cell regeneration was also demonstrated with Momordica 
charantia (Hafizur et al., 2011; Singh & Gupta, 2007b), Cantaranthus roseus (Ahmed et al., 2010), Nigella sativa 
(Abdelmeguid et al., 2010; Kanter et al., 2009), Allium sativum (Albajali et al., 2011) and Syzygium cumini (Singh & 
Gupta, 2007a). These findings suggest that these extracts can potentially cure Type 1 DM as well as play an important role 
in management of Type 2 DM. 
 
Increase in insulin sensitivity and glucose uptake 
One of the most prominent features of Type 2 DM is insulin resistance often times as a result of obesity (Boden & 
Shulman, 2002; Inzucchi et al., 2012). Several studies assessing the effects of traditional herbal medicines on insulin 
sensitivity and glucose uptake have been conducted. A protein from fresh fruit pulp of M. charantia increased the uptake of 
2-deoxyglucose in C2C12 cells (from the myocyte) in-vitro by 28%  comparable to 37% increase in uptake induced by 
insulin (Yibchok-anun et al., 2006). This could be due to a direct effect of the extract on GLUT-4 transporters in the muscle 
cells or promotion of the translocation of these transporters resulting in the increase in glucose uptake. In the same study, 
M. charantia protein extract and insulin also increased 2-deoxyglucose uptake in 3T3-L1 adipocytes by 2.4 fold and 6.3 
fold respectively, compared to the basal control group (Yibchok-anun et al., 2006). The ethyl acetate extract from M. 
charantia was also shown to activate both PPAR γ and α receptors leading to the modulation of insulin receptors. This 
could explain the increase in insulin sensitivity and glucose utilization in muscle cells and adipocytes (Chao & Huang, 
2003; Chuang et al., 2006).  
The effect of Coptis sinensis extracts on glucose homeostasis has been attributed to berberine, commonly present 
in the plant rhizomes, bark, roots and stems of the plant. Administration of berberine (200mg daily), via oral gavage in 
diabetic rats decreased fasting blood glucose levels, triglycerides, low density lipoproteins and total cholesterol and 
increased high density lipoprotein levels (Yu et al., 2005). Berberine increases GLUT 4 translocation in both myotubes and 
adipocytes (Kaleem et al., 2006), increases the expression of PPAR γ and α proteins in the liver (Zhou & Zhou, 2010; Zhou 
et al., 2008), increases the expression of insulin receptors in both the skeletal muscles and liver; and increases glucose 
uptake by glucose utilizing tissues in the presence of insulin (Kong et al., 2009).  
 
Alpha glucosidase and alpha amylase inhibition 
Alpha amylases and alpha glucosidases are responsible for breakdown of complex polysaccharides to 
oligosaccharides, disaccharides, and glucose. Inhibition of these enzymes decreases the rate of glucose absorption resulting 
in a decrease in post prandial blood glucose levels. Several herbal medicines have been shown to inhibit alpha glucosidase 
and amylase enzymes. The plants include, guava leaves (Wang et al., 2010), Adhatoda vasica (Gao et al., 2008), Baccharis 
trimera (Oliveira et al., 2005), Bergenia ciliate (Bhandari et al., 2008), Brachylaena discolor (Mellem et al., 2015), G. 
sylvestre (Luo et al., 2001), M. charantia (Uebanso et al., 2007), Phyllantus amarus (Ali et al., 2006), Pinus densiflora 
(Kim et al., 2005; Schäfer & Högger, 2007), and Tourbefortia hartwegiana (Ortiz-Andrade et al., 2007).  
 
Dipeptidyl peptidase IV (DPP-IV) inhibition 
The DPP-IV enzyme is responsible for the breakdown of incretin hormones (GLP-1 and Glucose-dependent 
insulinotropin polypetide). Incretin hormones increase insulin synthesis and release from pancreatic beta cells and reduce 
glucagon secretion from pancreatic alpha cells. Therefore, the inhibition of DPP-IV results in increased insulin synthesis 
and release and reduce glucagon secretion. Protein hydrolyzates from Amarantus hypochondriacus reduced postprandial 
glycemia in streptozotocin-induced diabetic mice, possibly through inhibition of DPP-IV as observed in an in-vitro study 
(Soriano-Santos et al., 2015). 
 
Sodium-glucose transporter - 1 (SGLT-1) inhibition 
SGLT-1 is a transporter that is found in the brush border of the small intestines which is responsible for absorption 
of glucose. Therefore, inhibition of SGLT-1, just like alpha glucosidase inhibitors, results in decreased absorption of 
glucose in the small intestines.  The models to study inhibition of SGLT-1 include brush border membrane vesicles 
(BBMV) prepared from apical membrane and vesicles prepared from basolateral membrane (BLMV) of the small intestines 
(Soumyanath, 2005). Extracts of G. sylvestre were shown to inhibit intestinal SGLT-1 and hence reduce absorption of 
glucose from the small intestines (Y. Wang et al., 2014). Extracts of T. foenun-graecum, Camellia sinensis  and Green Tea 
Polyphenols inhibited glucose absorption in BBMV models (Al-Habori et al., 2001)’ (Kobayashi et al., 2000). Since there 
is no SGLT-1 inhibitor among the conventional anti-diabetic medicines, this is an important area of future research.  
A comparison of the mechanisms of action of conventional and some herbal medicines is summarized in the table 
below.
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Table: Comparison of mechanisms of action of conventional medicines with TM 
 
 Decreased rate 
of 
carbohydrate 
absorption 
Stimulation of 
insulin 
secretion 
Activation of 
PPAR 
Increase in 
insulin 
receptor 
sensitivity 
Regeneration 
or decrease in 
apoptosis of 
B-cells  
Antioxidant 
activity 
Increase in 
glucose 
excretion 
Conventional Medicines        
Alpha glucosidase inhibitors *       
Amylinomimetics * *      
Biguanides    *    
DPP-IV inhibitors  *      
GLP-1 agonists  *      
Meglitinides  *      
SGLT-2 inhibitors       * 
Sulfonylureas  *      
Thiazolidinediones   *     
 
Herbal medicines 
       
Adhatoda vasica *       
Allium sativum     * *  
Brachylaena discolor *       
Camelia sinensis *     * * 
Catharanthus roseus     * *  
Coptis sinensis   * * * *  
G.sylvestre * *  * * *  
M. charantia * * * * * *  
Nigella sativa     * *  
Panax ginseng    *  *  
Phyllantus amarus *       
Rhus hirta      *  
Solidago Canadensis      *  
Syzygium cumini     * *  
T. foenum-graecum * *   * *  
Tourbefortia hartwegiana *       
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Conclusion 
 
Clearly, herbal medicines have multiple mechanisms possibly because of the multiple phytoconstituents, which 
effectively make them combination therapies. In addition, the multiple phytoconstituents may make traditional herbal 
medicines effective for the whole metabolic syndrome compared to conventional medicines that mainly focus on diabetes 
with limited or no effect on the other pathophysiological pathways of the metabolic syndrome.  
The review has discussed several in-vitro and in-vivo models that have been used to evaluate efficacy and study 
possible mechanisms of action of herbal medicines used to treat diabetes. Clearly, there is need for consensus on the 
minimum evidence that is required to conclude that a particular traditional medicine is truly anti-diabetic, and build the 
necessary evidence towards human studies. This means that a minimum algorithm of in-vitro and in-vivo models to assess 
the anti-diabetic effects of herbal medicines is therefore required.  
Amongst the in-vitro models, alpha glucosidase inhibition and antioxidant activity have been extensively used in 
evaluating anti-diabetic potential of traditional herbal medicines. Models that assess the other potential mechanisms of 
action need to be developed, optimized and utilized in diabetes research. Research should also focus on improving the 
action of traditional herbal medicines in the forms used by the traditional healers as much as it focuses on isolation of active 
chemical entities. 
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